Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1190-1194

  Ramaswamy, Vijay ^a,b   Remke, Marc ^a,b   Shih, David ^a,b   Wang, Xin ^a,b   Northcott, Paul A ^c   Faria, Claudia C ^a,d   Raybaud, Charles ^a   Tabori, Uri ^a   Hawkins, Cynthia ^a,b   Rutka, James ^a   Taylor, Michael D ^a,b   Bouffet, Eric ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Genomics; Medulloblastoma; Pediatric brain tumor; Pre diagnostic interval; Subgroups

Indexed keywords

SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ADOLESCENT; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE DURATION; GENE EXPRESSION; GROUPS BY AGE; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDULLOBLASTOMA; NEUROSURGERY; OVERALL SURVIVAL; POST HOC ANALYSIS; POSTERIOR CRANIAL FOSSA TUMOR; POSTERIOR FOSSA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD; TISSUE SECTION; TUMOR LOCALIZATION; TUMOR VOLUME;

GENOMICS; MEDULLOBLASTOMA; PEDIATRIC BRAIN TUMOR; PRE-DIAGNOSTIC INTERVAL; SUBGROUPS;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84899668093     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25002     Document Type: Article

References (33)

1. CBTRUS. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL; 2011.
2. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: The recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 2011; 204:577-588.
3. Dixon-Woods M, Findlay M, Young B, et al. Parents' accounts of obtaining a diagnosis of childhood cancer. Lancet 2001; 357:670-674.
4. Gerber NU, von Hoff K, von Bueren AO, et al. A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. Eur J Cancer 2012; 38:2028-2036.
5. Brasme J-F, Grill J, Doz F, et al. Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome. PLoS ONE 2012; 7:e33415.
6. Brasme J-F, Morfouace M, Grill J, et al. Delays in diagnosis of paediatric cancers: A systematic review and comparison with expert testimony in lawsuits. Lancet Oncol 2012; 13:e445-e459.
7. Mehta V, Chapman A, McNeely PD, et al. Latency between symptom onset and diagnosis of pediatric brain tumors: An Eastern Canadian geographic study. Neurosurgery 2002; 51:365-372, discussion 372-373.
8. Kukal K, Dobrovoljac M, Boltshauser E, et al. Does diagnostic delay result in decreased survival in paediatric brain tumours? Eur J Pediatr 2008; 168:303-310.
9. Brasme J-F, Chalumeau M, Doz F, et al. Interval between onset of symptoms and diagnosis of medulloblastoma in children: Distribution and determinants in a population-based study. Eur J Pediatr 2011; 171:25-32.
10. Cecen E, Gunes D, Mutafoglu K, et al. The time to diagnosis in childhood lymphomas and other solid tumors. Pediatr Blood Cancer 2011; 57:392-397.
11. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer 2012; 12:818-834.
12. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
13. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 2011; 123:465-472.
14. Remke M, Hielscher T, Korshunov A, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011; 29:3852-3861.
15. Dubuc AM, Morrissy AS, Kloosterhof NK, et al. Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol 2012; 123:485-499.
16. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41:465-472.
17. Northcott PA, Hielscher T, Dubuc A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 2011; 122:231-240.
18. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 2012; 488:49-56.
19. Dubuc AM, Remke M, Korshunov A, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 2012; 125:373-384.
20. Northcott PA, Fernandez-L A, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009; 69:3249-3255.
21. Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012; 482:529-533.
22. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-484.
23. Cho Y-J, Tsherniak A, Tamayo P, et al. Integrative Genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424-1430.
24. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29:2717-2723.
25. Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012; 8:340-351.
26. Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol 2013; 14:1200-1207.
27. Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013; 126:917-929.
28. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012; 123:615-626.
29. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28:1345-1350.
30. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927-2935.
31. Halperin EC, Watson DM, George SL. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer 2001; 91:1444-1450.
32. Pfaff E, Remke M, Sturm D, et al. TP53 mutation is frequently associated with CTNNB1 Mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010; 28:5188-5196.
33. Reulecke BC, Erker CG, Fiedler BJ, et al. Brain tumors in children: Initial symptoms and their influence on the time span between symptom onset and diagnosis. J Child Neurol 2007; 23:178-183.